MT-ND4 and Leber hereditary optic neuropathy: It remains to be determined by clinical trials whether our MTS AAV-ND4 will benefit LHON patients with a) chronic or b) acute visual loss or c) fellow eyes with good vision that are destined to go blind in approximately two months after visual loss in the opposite eye and d) how long the beneficial effect will last.